Oricell Therapeutics said it raised more than $100 million in a pre-IPO round to support development of Ori-C101, a GPC3-targeted autologous CAR-T aimed at hepatocellular carcinoma. The company reported that the therapy completed a Phase 1 study across three dose levels in 10 patients, with the highest dose delivering an objective response. The financing comes with backing from investors including E-Town Capital, Luxin Venture Capital and NGS Super, while Vivo Capital and other partners co-led the round, according to an April 9 release. Oricell said proceeds will fund global expansion, clinical development and technological capabilities. Oricell’s management framed the next steps as making Ori-C101 the first globally approved CAR-T for HCC, while also advancing in vivo CAR-T and solid-tumor CAR-T programs. The funding follows earlier rounds spanning a $125 million Series B in 2022, a $45 million B1 in 2023 and a $70 million Series C1 described earlier this year.